Forte Biosciences (NASDAQ:FBRX) Price Target Raised to $64.00

Forte Biosciences (NASDAQ:FBRX) had its price objective increased by Chardan Capital from $3.00 to $64.00 in a research note issued to investors on Friday,Benzinga reports. The firm currently has a buy rating on the stock.

Forte Biosciences Price Performance

Shares of FBRX stock opened at $5.84 on Friday. The firm has a market cap of $8.53 million, a price-to-earnings ratio of -0.36 and a beta of 0.04. The stock’s fifty day simple moving average is $5.49 and its 200 day simple moving average is $2.33. Forte Biosciences has a one year low of $4.11 and a one year high of $21.25.

Forte Biosciences Company Profile

Forte Biosciences, Inc operates as a biopharmaceutical company in the United States. The company is developing FB-102 program that addresses various autoimmune diseases, such as graft-versus-host disease, and vitiligo and alopecia areata. Forte Biosciences, Inc is headquartered in Dallas, Texas.